FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2406456122> ?p ?o ?g. }

• W2406456122 abstract "Introduction: Rolapitant is a selective and long acting NK-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting (CINV). In vitro results indicated rolapitant mildly inhibited cytochrome P450 (CYP450) enzymes (2D6/2C9/2C19/2B6/2C8) at high concentrations (IC50s > 7 μM). The major metabolite SCH720881 did not inhibit these CYP enzymes. This study aimed to 1) evaluate the effects of rolapitant on the pharmacokinetics (PK) of CYP probe substrates (dextromethorphan [DET] for CYP2D6, tolbutamide [TOL] for CYP2C9, omeprazole [OMP] for CYP2C19, efavirenz [EFA] for CYP2B6 and repaglinide [REP] for CYP2C8), and 2) evaluate the safety and tolerability of rolapitant co-administered with these substrates in healthy subjects. Methods: This was an open-label, multi-part drug-drug interaction study in cohorts of 20 to 26 healthy subjects of orally-administered CYP probe substrates (Part-A: 30 mg DET; Part-B: 500 mg TOL plus 40 mg OMP; Part-C: 600 mg EFA; Part-D: 0.25 mg REP) in the absence and presence of single oral dose 180 mg rolapitant. Blood samples for determination of plasma concentration of CYP substrates and relevant metabolites were collected during 3 dosing periods in each part: 1) Period-1: CYP probe substrate alone as baseline; 2) Period-2: CYP probe substrate plus rolapitant concomitantly after a washout of probe given in Period 1 to evaluate the potential impact of rolapitant on probe substrate; and 3) Period-3: CYP probe substrate alone 7 days after the concomitant dose in Period-2 (approximating the peak time of metabolite SCH720881) to evaluate the impact of metabolite/rolapitant on probe substrate. Results: Rolapitant inhibited CYP2D6 following concomitant dose (Period-2) and 7 days after concomitant dose (Period-3), resulting in 2.2- to 3.3-fold higher exposure (Cmax and AUC) of DET. Rolapitant did not inhibit CYP2C9 following exposure to TOL. The exposure (Cmax & AUC) of CYP2C19 substrate OMP was minimally increased by rolapitant (1.1- to1.4-fold) and is unlikely to be clinically relevant. Rolapitant did not inhibit CYP2B6 or result in clinically relevant changes in exposure of EFA. Rolapitant did not inhibit CYP2C8 or result in clinically relevant changes in exposure of REP. There were no noteworthy adverse events or laboratory findings in any part of the study. Conclusions: Rolapitant was well-tolerated when co-administered with CYP probe substrates. Co-administration of rolapitant increased the exposure of DET. The inhibition of CYP2D6 can last at least 7 days following single dose of rolapitant. No clinically significant interaction was observed between rolapitant and substrates of CYP2C9, CYP2C19, CYP2B6 or CYP2C8; therefore no dosing adjustment is necessary for drugs which are metabolized by these CYPs. Citation Format: Xiaodong Wang, Zhi-Yi Zhang, Jing Wang, Sharon Lu, Sujata Arora, Lorraine Hughes, Jennifer Christensen, Vikram Kansra. Effects of rolapitant on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C62." @default.
• W2406456122 created "2016-06-24" @default.
• W2406456122 creator A5001035529 @default.
• W2406456122 creator A5015250372 @default.
• W2406456122 creator A5023923887 @default.
• W2406456122 creator A5037677450 @default.
• W2406456122 creator A5040205022 @default.
• W2406456122 creator A5080820559 @default.
• W2406456122 creator A5083020431 @default.
• W2406456122 creator A5085724211 @default.
• W2406456122 date "2015-12-01" @default.
• W2406456122 modified "2023-09-25" @default.
• W2406456122 title "Abstract C62: Effects of rolapitant on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects" @default.
• W2406456122 doi "https://doi.org/10.1158/1535-7163.targ-15-c62" @default.
• W2406456122 hasPublicationYear "2015" @default.
• W2406456122 type Work @default.
• W2406456122 sameAs 2406456122 @default.
• W2406456122 citedByCount "2" @default.
• W2406456122 countsByYear W24064561222017 @default.
• W2406456122 countsByYear W24064561222018 @default.
• W2406456122 crossrefType "proceedings-article" @default.
• W2406456122 hasAuthorship W2406456122A5001035529 @default.
• W2406456122 hasAuthorship W2406456122A5015250372 @default.
• W2406456122 hasAuthorship W2406456122A5023923887 @default.
• W2406456122 hasAuthorship W2406456122A5037677450 @default.
• W2406456122 hasAuthorship W2406456122A5040205022 @default.
• W2406456122 hasAuthorship W2406456122A5080820559 @default.
• W2406456122 hasAuthorship W2406456122A5083020431 @default.
• W2406456122 hasAuthorship W2406456122A5085724211 @default.
• W2406456122 hasConcept C109650736 @default.
• W2406456122 hasConcept C112705442 @default.
• W2406456122 hasConcept C126322002 @default.
• W2406456122 hasConcept C140840227 @default.
• W2406456122 hasConcept C149151106 @default.
• W2406456122 hasConcept C181199279 @default.
• W2406456122 hasConcept C185592680 @default.
• W2406456122 hasConcept C2776054734 @default.
• W2406456122 hasConcept C2777477808 @default.
• W2406456122 hasConcept C2777498785 @default.
• W2406456122 hasConcept C2779306644 @default.
• W2406456122 hasConcept C2779591118 @default.
• W2406456122 hasConcept C2781245242 @default.
• W2406456122 hasConcept C33664856 @default.
• W2406456122 hasConcept C3946865 @default.
• W2406456122 hasConcept C50605568 @default.
• W2406456122 hasConcept C526171541 @default.
• W2406456122 hasConcept C55493867 @default.
• W2406456122 hasConcept C71924100 @default.
• W2406456122 hasConcept C98274493 @default.
• W2406456122 hasConceptScore W2406456122C109650736 @default.
• W2406456122 hasConceptScore W2406456122C112705442 @default.
• W2406456122 hasConceptScore W2406456122C126322002 @default.
• W2406456122 hasConceptScore W2406456122C140840227 @default.
• W2406456122 hasConceptScore W2406456122C149151106 @default.
• W2406456122 hasConceptScore W2406456122C181199279 @default.
• W2406456122 hasConceptScore W2406456122C185592680 @default.
• W2406456122 hasConceptScore W2406456122C2776054734 @default.
• W2406456122 hasConceptScore W2406456122C2777477808 @default.
• W2406456122 hasConceptScore W2406456122C2777498785 @default.
• W2406456122 hasConceptScore W2406456122C2779306644 @default.
• W2406456122 hasConceptScore W2406456122C2779591118 @default.
• W2406456122 hasConceptScore W2406456122C2781245242 @default.
• W2406456122 hasConceptScore W2406456122C33664856 @default.
• W2406456122 hasConceptScore W2406456122C3946865 @default.
• W2406456122 hasConceptScore W2406456122C50605568 @default.
• W2406456122 hasConceptScore W2406456122C526171541 @default.
• W2406456122 hasConceptScore W2406456122C55493867 @default.
• W2406456122 hasConceptScore W2406456122C71924100 @default.
• W2406456122 hasConceptScore W2406456122C98274493 @default.
• W2406456122 hasLocation W24064561221 @default.
• W2406456122 hasOpenAccess W2406456122 @default.
• W2406456122 hasPrimaryLocation W24064561221 @default.
• W2406456122 hasRelatedWork W1484997091 @default.
• W2406456122 hasRelatedWork W1510445847 @default.
• W2406456122 hasRelatedWork W1853900357 @default.
• W2406456122 hasRelatedWork W188698896 @default.
• W2406456122 hasRelatedWork W1963505261 @default.
• W2406456122 hasRelatedWork W2089539668 @default.
• W2406456122 hasRelatedWork W2091987664 @default.
• W2406456122 hasRelatedWork W2109376915 @default.
• W2406456122 hasRelatedWork W2120703255 @default.
• W2406456122 hasRelatedWork W2399887147 @default.
• W2406456122 hasRelatedWork W2566129960 @default.
• W2406456122 hasRelatedWork W2583100802 @default.
• W2406456122 hasRelatedWork W2765589989 @default.
• W2406456122 hasRelatedWork W2885031069 @default.
• W2406456122 hasRelatedWork W2948884054 @default.
• W2406456122 hasRelatedWork W2966323023 @default.
• W2406456122 hasRelatedWork W3034732559 @default.
• W2406456122 hasRelatedWork W3036961005 @default.
• W2406456122 hasRelatedWork W3087909260 @default.
• W2406456122 hasRelatedWork W3111241198 @default.
• W2406456122 isParatext "false" @default.
• W2406456122 isRetracted "false" @default.
• W2406456122 magId "2406456122" @default.
• W2406456122 workType "article" @default.